Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.

Article Details

Citation
Copy to clipboard

Ascher DB, Wielens J, Nero TL, Doughty L, Morton CJ, Parker MW

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.

Sci Rep. 2014 Apr 23;4:4765. doi: 10.1038/srep04765.

PubMed ID
24755925 [ View in PubMed
]
Abstract

Hepatitis C virus (HCV) infection affects more than 170 million people. The high genetic variability of HCV and the rapid development of drug-resistant strains are driving the urgent search for new direct-acting antiviral agents. A new class of agents has recently been developed that are believed to target the HCV protein NS5A although precisely where they interact and how they affect function is unknown. Here we describe an in vitro assay based on microscale thermophoresis and demonstrate that two clinically relevant inhibitors bind tightly to NS5A domain 1 and inhibit RNA binding. Conversely, RNA binding inhibits compound binding. The compounds bind more weakly to known resistance mutants L31V and Y93H. The compounds do not affect NS5A dimerisation. We propose that current NS5A inhibitors act by favouring a dimeric structure of NS5A that does not bind RNA.

DrugBank Data that Cites this Article

Drugs